New antibody A-319 takes aim at Hard-to-Treat lupus

NCT ID NCT06400537

Recruiting now Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called A-319 in 25 people with active or treatment-resistant systemic lupus erythematosus (SLE). A-319 is a type of antibody designed to target and help control the immune system cells that drive lupus. The main goal is to see if the drug is safe and tolerable, while also looking at how it affects the body and whether it shows any signs of controlling the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A-319 (a CD19xCD3 bispecific antibody)
What this could lead to: If successful, this could point toward a new treatment option for people with lupus that is not controlled by current therapies.
What could go wrong: This is a very early Phase 1 trial with only 25 participants, so safety and effectiveness are not yet proven. The treatment may cause side effects or fail to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Shanxi Bethune Hospital
RECRUITING

Taiyuan, Shanxi, 030032, China
Wuhan Union Hospital
RECRUITING

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.